Acrivon Therapeutics

Recent Finacing

Equity

Recent Raise

$130M

Acrivon Therapeutics develops the CHK1/2 inhibitor ACR-368 in Phase-2 while using its AP3 phospho-proteomic platform and OncoSignature companion diagnostics to enroll patients and operate discovery hubs in Lund and Watertown.

Founded 2018

Massachusetts, United States

51-100

Publicly Traded

acrivon.com

Highlights

Focus Areas

Biotechnology

Health Care

Oncology

Therapeutics

Recent Investors

C

Financials

$230M

Total Raised

2

Funding rounds

12

Investors

Team

Upgrade to view the team

See the team members at Acrivon Therapeutics.